StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.41+0.01 (+2.12%)

Close on Nov 18, 2026Market cap $113.31MP/E –Yield –

Akebia Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Akebia Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $219.06M, up 7.5% year over year. For fiscal 2025 it was $236.20M, up 47.5% from the year before. The highest annual figure on record is $335.00M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$236.20M+47.5%
FY2024Dec 31, 2024$160.18M-17.7%
FY2023Dec 31, 2023$194.62M-33.5%
FY2022Dec 31, 2022$292.48M+38.2%
FY2021Dec 31, 2021$211.65M-28.2%
FY2020Dec 31, 2020$294.64M-12.0%
FY2019Dec 31, 2019$335.00M+61.3%
FY2018Dec 31, 2018$207.74M+14.6%
FY2017Dec 31, 2017$181.23M+11706.3%
FY2016Dec 31, 2016$1.54M–
FY2015Dec 31, 2015$0–
FY2014Dec 31, 2014$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$49.13M-21.4%
Q1 FY2026Mar 31, 2026$53.54M-6.6%
Q4 FY2025Dec 31, 2025$57.62M+23.9%
Q3 FY2025Sep 30, 2025$58.77M+57.0%
Q2 FY2025Jun 30, 2025$62.47M+43.1%
Q1 FY2025Mar 31, 2025$57.34M+75.8%
Q4 FY2024Dec 31, 2024$46.50M-17.3%
Q3 FY2024Sep 30, 2024$37.43M-11.0%
Q2 FY2024Jun 30, 2024$43.65M-22.6%
Q1 FY2024Mar 31, 2024$32.61M-18.5%
Q4 FY2023Dec 31, 2023$56.20M+0.7%
Q3 FY2023Sep 30, 2023$42.05M-13.7%
Q2 FY2023Jun 30, 2023$56.38M-55.4%
Q1 FY2023Mar 31, 2023$40.01M-35.2%
Q4 FY2022Dec 31, 2022$55.78M-3.3%
Q3 FY2022Sep 30, 2022$48.71M-0.1%
Q2 FY2022Jun 30, 2022$126.37M+138.8%
Q1 FY2022Mar 31, 2022$61.70M+18.0%
Q4 FY2021Dec 31, 2021$57.68M+2.9%
Q3 FY2021Sep 30, 2021$48.76M-18.7%
Q2 FY2021Jun 30, 2021$52.91M-41.3%
Q1 FY2021Mar 31, 2021$52.30M-40.9%
Q4 FY2020Dec 31, 2020$56.04M-19.4%
Q3 FY2020Sep 30, 2020$59.99M-34.8%
Q2 FY2020Jun 30, 2020$90.14M-10.6%
Q1 FY2020Mar 31, 2020$88.48M+21.8%
Q4 FY2019Dec 31, 2019$69.56M+16.2%
Q3 FY2019Sep 30, 2019$91.98M+73.0%
Q2 FY2019Jun 30, 2019$100.80M+106.6%
Q1 FY2019Mar 31, 2019$72.67M+58.2%
Q4 FY2018Dec 31, 2018$59.85M-33.9%
Q3 FY2018Sep 30, 2018$53.17M+28.8%
Q2 FY2018Jun 30, 2018$48.79M+71.1%
Q1 FY2018Mar 31, 2018$45.93M+2892.2%
Q4 FY2017Dec 31, 2017$90.56M–
Q3 FY2017Sep 30, 2017$41.28M–
Q2 FY2017Jun 30, 2017$28.52M–
Q4 FY2016Dec 31, 2016$1.54M–
Q3 FY2016Sep 30, 2016$0–

More Akebia Therapeutics figures

See a number that looks wrong?